Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease.
Andree H KoopPaul M TraversSahil KhannaDarrell S PardiFrancis A FarrayeJana G HashashPublished in: Journal of gastroenterology and hepatology (2023)
In this cohort of patients with inflammatory bowel disease and C. difficile infection, 60.6% responded to treatment with fidaxomicin. Of those who did not respond, fecal microbiota transplantation was an effective therapy.